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The risks of using allogeneic cell lines for vaccine production: the example of Bovine
Neonatal Pancytopenia
Lindert Benedictus a,b* and Charlotte R. Bell c*
aDepartment of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands; bDepartment of
Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands; cThe Roslin Institute and Royal (Dick) School of Veterinary
Studies, University of Edinburgh, Easter Bush, Midlothian, Scotland, UK
ABSTRACT
Introduction: Bovine neonatal pancytopenia (BNP) is a hemorrhagic disease that emerged in calves
across Europe in 2007. Its occurrence is attributed to immunization of the calf’s mother with a vaccine
produced using an allogeneic cell line. Vaccine-induced alloantibodies specific for major-histocompat-
ibility class I antigens are transferred from the mother to the calf via colostrum, leading to profound
depletion of peripheral blood and bone marrow cells that is often fatal.
Areas covered: Pubmed and Web of Science were used to search for literature relevant to BNP and the
use of allogeneic vaccine cell lines. Following a review of the pathology and pathogenesis of this novel
condition, we discuss potential risks associated with the use of allogeneic vaccine cell lines.
Expert commentary: Although BNP is associated with a specific vaccine, it highlights safety concerns
common to all vaccines produced using allogeneic cell lines. Measures to prevent similar vaccine-
induced alloimmune-mediated adverse events in the future are discussed.
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1. The emergence of a novel disease
In 2007 a novel hemorrhagic disease emerged in calves across
Europe, characterized by profound depletion of peripheral blood
and bone marrow cells the disease was named bovine neonatal
pancytopenia (BNP) [1,2]. By February 2011 the deaths of more
than 4500 calves in Europe had been attributed to BNP [3] and
many more cases were undoubtedly unreported [4]. From 2011
BNP cases also appeared in New Zealand [5]. No infectious agent,
myelosuppressive toxin or genetic defect could be identified as
the cause of the disease [1,2,6,7] and, as the incidence on most
affected farmswas low (usually <10%), determining the pathogen-
esis proved to be challenging. It is now clear that BNP is caused by
vaccine-induced maternal alloantibodies which are transferred
from mother to calf via the colostrum (first milk rich in maternal
antibodies). These alloantibodies, which are specific for major
histocompatibility complex class I (MHC I) molecules, are gener-
ated in response to residual cell-line material found within a
specific vaccine containing a novel adjuvant formulation [8–12].
BNP therefore highlights important issues regarding the safety of
using allogeneic cell lines for vaccine production. In this review,
the pathology andpathogenesis of BNP are described, followedby
a discussion of the implications for vaccine safety in general and
possible measures to avoid similar adverse effects in the future.
2. Clinical signs and pathology of BNP
Calves affected by BNP show no abnormalities at birth, their
mothers are unaffected and there is no increase in abortion
rate in affected herds [1,2,13]. Onset of clinical disease is
usually between 7 and 28 days of age with signs of external
and internal hemorrhage and petechiation [1,2,13,14]. Rapid
internal bleeding can result in affected calves being found
dead with no external signs of hemorrhage, contributing to
the under-reporting of cases [4]. Intercurrent infections are
common and often result in profound pyrexia [2,13,15]. The
majority (80–90%) of clinically affected calves die or are eutha-
nized soon after the onset of symptoms [2,13], however in
some cases recovery from the condition is possible [2,13].
Hematology from BNP cases reveals a profound thrombo-
cytopenia and leukopenia [2,13] and histopathology of bone
marrow shows extensive depletion of hematopoietic cells
(Figure 1). Experimental studies reproducing the disease
demonstrated that as early as 4 h following ingestion of
alloantibodies there is already a 75–95% reduction in periph-
eral blood lymphocytes, monocytes and neutrophils [16,17].
Detailed analysis of the time-course of hematological and
bone marrow alterations indicates initial peripheral thrombo-
cyte and leukocyte destruction followed by damage to hema-
topoietic precursors, with more profound damage to
mononuclear lineages and relative sparing of granulocytes
[16]. While there is no damage to peripheral erythrocytes,
cases develop a normocytic, normochromic, nonregenerative
anemia, presumably reflecting a failure to respond to hemor-
rhage due to loss of early erythroid precursor cells. Cellular
depletion of other lymphoid tissues appears to be variable and
there is no evidence of primary damage to the parenchyma of
other organs or to the vascular endothelium [2,13].
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3. The pathogenesis of Bovine Neonatal
Pancytopenia
3.1. BNP is an alloimmune disease induced by antibodies
absorbed from colostrum
Early investigations found that colostrum obtained from cows
that had previously given birth to a BNP-affected calf (BNP
cows) causes BNP when fed to unrelated newborn calves [15–
18]. Furthermore, serum and colostrum from BNP cows were
shown to contain alloantibodies that bind to peripheral blood
leukocytes, platelets and bone marrow cells [9,11,12,18–21],
and intravenous infusion of these antibodies was sufficient to
induce the disease [9]. The bovine epitheliochorial placenta
presents a complete barrier to the transfer of immunoglobu-
lins from the cow to the fetus, and thus the calf is completely
dependent on ingestion of colostrum for maternal immuno-
globulin transfer [22], explaining why BNP only occurs post-
partum. Moreover, differences in immunoglobulin
concentrations in colostrum, the quantity ingested and the
time from birth to suckling, which affects efficiency of immu-
noglobulin absorption, will all contribute to the final amount
of maternal immunoglobulin absorbed by the calf [23–25].
Thus these factors will contribute to variability in the like-
lihood of a calf developing BNP and the extent of alloanti-
body-induced pathology (Figure 2) [26].
3.2. Vaccination induces BNP-associated alloantibodies
Confirmation that BNP is mediated by colostrum derived
alloantibodies prompted the question: what induced the pro-
duction of alloantibodies by BNP cows? Epidemiological stu-
dies demonstrated a significant association between BNP and
the administration of a specific vaccine (Pregsure© BVD, Pfizer
Animal Health) to the mothers of affected calves [26–28] and
showed that the incidence of BNP was higher in herds that
received multiple doses of the vaccine [10]. It was also notable
that those European countries that remained free from BNP
prohibited the use of this and all other BVD vaccines, due to
alternative disease control policies. Pregsure© is an inactivated
vaccine for the prevention of bovine viral diarrhea (BVD) virus
and was launched in Europe in 2004 [14] and in New Zealand
in 2008 [29]. To manufacture this vaccine, BVD virus is cultured
in Madin–Darby bovine kidney (MDBK) cells [30] and, follow-
ing purification, combined with a novel proprietary adjuvant
(Procison-ATM; a micro-fluidized oil-in-water adjuvant com-
posed of Quil-A, Cholesterol, mineral oil [31]). High levels of
residual bovine proteins have been detected in Pregsure©
[8,9,32] and alloantibodies from BNP cows have been shown
to recognize MDBK cells [8,9,12,19]. Furthermore, experimental
immunization of calves with Pregsure© confirmed that vacci-
nation induces alloantibodies that bind MDBK cells and leu-
kocytes [10,19]. Together, these findings demonstrate that
alloantigens present in Pregsure© induced maternal alloanti-
bodies that, upon absorption from colostrum, caused BNP in
calves.
Pregsure© was withdrawn from the European market in
2010, following reports of its association with BNP, but cases
continue to be seen in previously vaccinated animals [33].
(a) (b)
Figure 1. Histological findings from femoral bone marrow from: (a) a field case of BNP euthanized at approximately 3 weeks old, showing almost total loss of
hematopoietic cells and their replacement by erythrocytes and proteinaceous fluid and (b) an unaffected healthy calf, showing normal high cellularity with little
fatty stromal tissue apparent. Haematoxylin and Eosin. Bars = 100 µm. (reproduced with permission from BMJ Publishing Group Limited. Idiopathic bovine neonatal
pancytopenia in a Scottish beef herd [2]).
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Figure 2. Diagram illustrating the multifactorial pathogenesis of BNP.
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3.3. Major histocompatibility complex class I molecules
are the major target antigens in BNP
By using sera from BNP cows to immunoprecipitate antigens
from the surface of MDBK cells [8] and peripheral blood leu-
kocytes [9], MHC I molecules were identified as a target of BNP
alloantibodies. Using transfected cell lines, sera from BNP cows
were also shown to bind specifically to the MHC I alleles
present on MDBK cells and to induce complement-mediated
cytotoxicity [11]. Furthermore, in vitro experiments showed
that BNP alloantibodies preferentially target cells with high
MHC I expression and that this correlates with the hemato-
poietic cell types affected in BNP [11,12,16] (Figure 2 and
Section 2). Using a modified MDBK cell line with no MHC I
expression (beta-2-microglobulin knockout) it was confirmed
that MHC I is the dominant target of BNP alloantibodies and
depending on the BNP dam accounts for 46–91% of the
alloantibody specificity [12]. Alloantibodies targeting alterna-
tive antigens (e.g. VLA-3) were also identified [12], however
only anti-MHC I alloantibodies were consistently found in BNP
cows and showed correlation with BNP pathology. Thus, over-
all evidence indicates that BNP alloantibodies are induced by
bovine cellular material, specifically MHC I molecules, found in
Pregsure© and that these alloantibodies account for the
damage to the hematopoietic system seen in BNP.
3.4. Following Pregsure© vaccination BNP cows develop
high anti-MHC I alloantibody titers with heterogeneous
specificities, and both the quantity and specificity of
these alloantibodies determine the risk of BNP in the calf
Despite the widespread use of Pregsure© the number of BNP
cases has been relatively low, with the incidence estimated to
be below 0.3% [19]. Even allowing for underreporting of cases,
it became clear that factors other than Pregsure© vaccination
alone must therefore determine whether BNP develops in the
calf.
Following identification of MHC I as the antigenic target in
BNP, it was hypothesized that epitope differences between
the MHC I alleles expressed by MDBK cells and a given cow
would determine the induction of alloantibodies and, conver-
sely, that epitope similarities between MDBK cells and a given
calf would determine its propensity to develop the disease
[8,9]. Subsequently this was supported by the finding that
Pregsure© vaccinated cows generate a unique profile of
MHC I-specific alloantibodies, presumably reflecting the
degree of alloantigen mismatch between their MHC I alleles
and those of the vaccine cell line [11,12]. However, the situa-
tion in calves appears to be more complex with BNP-alloanti-
bodies also showing varying degrees of cross reactivity with
MHC I alleles not present on MDBK cells [11,12]. This is con-
sistent with the nature of MHC I sequence polymorphism,
where short stretches of amino acids are frequently shared
by different alleles. Consequently, BNP cows and calves are
both likely to have a wide range of different MHC I genotypes,
which explains why no association has been found between
specific MHC haplotypes and the occurrence of BNP [34,35]
and why BNP is not a heritable trait for calves [35].
Pregsure© vaccinated BNP cows have significantly higher
serum alloantibody titers compared to both unvaccinated
cows and Pregsure© vaccinated non-BNP cows, however
alloantibodies are also found in Pregsure© vaccinated non-
BNP cows [11,19,35]. Among Pregsure© vaccinated cows
there appears to be a continuum of both alloantibody titer
and cross-reactivity, with those cows that produce clinically
affected calves having both higher serum alloantibody titers
and alloantibodies with broader specificity [11]. Together,
this suggests that the occurrence of BNP depends on the
quantity and specificity of the alloantibody dose absorbed by
the calf, implying that BNP is not a dichotomous disease but
that calves fall within a continuum from unaffected to severe
BNP cases depending on the effective cognate alloantibody
dose. This is consistent with the identification of milder sub-
clinical forms of BNP, where neonatal calves develop pro-
foundly abnormal hematology, including depressed
lymphocyte and monocyte counts but no clinical signs of
the condition [36,37]. Results from other studies indicate
that farms affected by BNP have increased levels of calf
morbidity attributable to causes other than BNP [4,28] pro-
viding a credible basis for the suggestion that subclinical BNP
could have an impact on calf health and productivity in
situations where animals are exposed to pathogen challenge.
In summary, the occurrence of BNP in the calf depends on
the quantity of the alloantibodies absorbed from colostrum,
which strongly depend on the alloantibody titer of the cow,
and the specificity of these antibodies for the MHC I alleles of
the calf (Figure 2).
3.5. High titers of BNP-alloantibodies persist in cows for
long periods of time
Following vaccination, serum antibody titers normally decline
with time. However, cows vaccinated with Pregsure© appear
to maintain high alloantibodies levels for years following last
vaccination [33], which explains why cases of BNP continue to
be seen despite the withdrawal of Pregsure© from sale.
Furthermore, pregnancy has been found to boost Pregsure©
induced alloantibody titers, resulting in high titers immedi-
ately prior to parturition (Figure 2) [33]. However the alloanti-
body specificity remains remarkably similar at subsequent
pregnancies [11], indicating that the fetus appears only to be
boosting existing Pregsure©-induced alloantibodies, rather
than stimulating novel alloantibodies. Whether other cattle
vaccines, many of which are also produced using MDBK cells,
play a role in maintaining or boosting existing BNP alloanti-
bodies has not yet been thoroughly investigated, but vaccines
other than Pregsure© have not been identified as risk factors
for the occurrence of BNP [26,28].
Among cows vaccinated with Pregsure©, BNP cows also
have higher BVD virus-specific antibody titers than non-BNP
cows [19], indicating that BNP cows responded with higher
antibody levels in general following vaccination. It is possible
that this reflects a genetic predisposition to respond robustly
to vaccination, as both BNP and other antibody titers follow-
ing vaccination have been shown to be heritable traits in cows
[35,38,39]. It is also notable that Pregsure© was an extremely
efficacious vaccine, generating robust and sustained immune
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responses to BVD virus [40] and significantly higher antibody
titers than other BVD vaccines [19], generally attributed to the
novel adjuvant it contains. It is interesting to speculate that
contaminant MHC I molecules within Pregsure© may them-
selves have immune stimulatory effects and so potentiate the
immune response to viral antigens, particularly given the cor-
relation between viral- and allo-antibody titers [19].
4. Expert commentary – the safety of using
allogeneic cell lines for vaccine production
The withdrawal of Pregsure© from the European market in
June 2010 will probably result in a gradual reduction in the
number of BNP cases, as cows vaccinated with the product are
culled. Nevertheless, the production of many vaccines requires
the use of allogeneic cell lines and, because complete purifica-
tion to remove all residual cell-line contamination is difficult
and costly, this raises the possibility of similar problems occur-
ring with other vaccines. Very low alloantibody titers have
been detected in cows and guinea pigs vaccinated with alter-
native BVD vaccines [8,19] and it could be speculated that
such responses might play a role in BNP-like cases that cannot
be linked to Pregsure© [26,41–43].
Several licensed human vaccines are produced using allo-
geneic cell lines and the number of different allogeneic lines
used has increased in recent years [44]. Licensing procedures
for human vaccines are more stringent than for veterinary
vaccines and antigen purification standards are higher.
However, it is difficult to assess what degree of cell-line con-
tamination is safe and this may depend on the particular
adjuvant or vaccine formulation, and the presence of preexist-
ing alloimmune responses (e.g. following pregnancy) which
might lower the threshold for responding to cell-line contami-
nants. Adjuvant and vaccine formulations that are able to
induce immune responses to low antigen levels or induce
very high antibody titers may pose an especially high risk in
combination with allogeneic cell lines. Furthermore, vaccinat-
ing mothers to protect infants is increasing in humans [45,46]
and this raises concerns for possible adverse alloimmune
effects in the fetus or neonate.
Calves rely solely on colostrum for maternal antibodies and
therefore receive a high alloantibody dose immediately after
birth leading to the acute onset of BNP. In contrast, transfer of
maternal antibodies in humans occurs during pregnancy,
which would lead to continued exposure of the fetus to
pathogenic alloantibodies during pregnancy. Accordingly,
adverse effects associated with vaccine-induced alloimmune
responses in humans are more likely to lead to early embryo-
nic loss, miscarriage or chronic conditions. Naturally occurring
MHC I specific alloantibodies have been associated with recur-
rent miscarriage and chronic chorioamnionitis in humans,
although studies have given conflicting results [47–49]. Early
embryonic loss and miscarriage are common in women and
nonspecific symptoms add to the complication of monitoring
for potential alloimmune related adverse vaccine effects. In
addition, the frequency of adverse effects is likely to be low
and may be complicated by the requirement for a specific
genetic background, as is the case in BNP. Due to the transfer
of antibodies during pregnancy in humans, preventing
alloimmune-mediated disorders would be more challenging
than the relatively straightforward colostrum substitution pos-
sible in cattle [50]. Furthermore, the maintenance of high
alloantibody titers in BNP dams for long periods suggests
that any historical exposure to such a product could still result
in pathology, and risks may therefore not be restricted to the
period immediately following vaccination.
To our knowledge there are no reports of alloimmune
related adverse effects due to vaccines produced on allo-
geneic cell lines in humans, however the possibility of such
effects does not appear to have been thoroughly investigated.
In the case of BNP, tolerance to self-antigens has not been
broken and hence transplant patients and (pregnant) woman
are likely to be most at risk of developing adverse reactions to
such vaccines. Influenza vaccination has been shown to gen-
erate alloantibodies in a very small number of people and,
although this prompted concerns regarding vaccination of
transplant patients, there were no associations with adverse
effects [51–53]. Comprehensive epidemiological studies are
needed to test whether vaccines grown on allogeneic cell
lines are associated with transplant rejection or poor preg-
nancy outcomes.
Testing for the induction of alloimmune responses follow-
ing vaccination could also be incorporated as an obligatory
assay during vaccine trials. However, since pathogenic alloim-
mune responses may only be induced in individuals with
specific genetic backgrounds or from demographic groups
not normally included in vaccine trials, and may also depend
on exposure to additional risk factors, it is important to
continue monitoring vaccines postlicensing. Testing for the
presence of alloantibodies is relatively straightforward and a
variety of assays have been employed in the case of BNP
[11,19]. Thus, testing for alloantibody responses in humans
during phase III vaccine trials, which generally involve many
hundreds of individuals, should detect even a relatively low
prevalence of responses. Indeed, while the prevalence of BNP
pathology is low, the prevalence of alloantibody production
in Pregsure© vaccinated cows is high; approximately 50% of
Pregsure© vaccinated animals develop alloantibodies how-
ever these only cause pathology in a small proportion of
calves depending on the absorbed alloantibody dose and
their specific MHC I haplotype [11,12]. Determining safe
threshold levels for alloantibody titers presents a greater
challenge, and in fact interpretation of alloantibody titers
still presents a challenge in transplant medicine [54].
However in this context BNP could have potential as a
model, given the possibility of performing controlled experi-
ments in MHC defined/matched animals, and the detailed
characterization of pathological changes observed during
disease, especially subclinical disease. Although the occur-
rence of BNP is associated with a specific vaccine, it serves
to emphasize safety concerns that are common to all vac-
cines produced using allogeneic cell lines and thus knowl-
edge gained from this disease could aid prevention of other
vaccine-induced alloimmune-mediated disorders.
Furthermore it highlights the need for careful scrutiny of
vaccines produced on allogeneic cell lines and underlines
the importance of monitoring for adverse vaccine reactions,
not just in vaccine recipients but also in their offspring, and
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the difficulties posed by such monitoring when signs may be
nonspecific and cases are likely to be infrequent.
5. Five-year view
In veterinary medicine pregnant animals are routinely vacci-
nated to optimize passive transfer of protective antibodies via
colostrum. In human medicine there is an increasing emphasis
on the health benefits for both mother and fetus afforded by
vaccination during pregnancy [46,55,56] and in the next five
years both the prevalence and range of vaccines given during
pregnancy will likely increase. While this is obviously to be
encouraged, the use of vaccines produced on allogeneic cell
lines around pregnancy must be accompanied by careful con-
siderations and it is likely that several steps will be taken in the
coming years to ensure the safe use of such vaccines.
First, during development and prelicensure trials, novel
vaccines should be tested for alloantigen contamination and
for the induction of alloimmune responses. Using BNP as a
model, it may be possible to define safe thresholds for both
these parameters. Secondly, it is important to be vigilant for
alloimmune related adverse events during trials and post-
licensing. Following recent guidance from the National
Institutes of Health [56] it is likely that existing and future
vaccines intended for use during pregnancy will include
clinical trials on pregnant women. However, the long-term
effects of maternal immunization among women and infants
have not been fully characterized [55], nor are risks posed by
vaccine-induced alloimmune responses to transplant recipi-
ents. Additionally, pathogenic alloimmune responses may
only be induced in specific populations not normally
included in vaccine trials, and may depend on exposure to
additional risk factors. Thus prelicensure trials need to be
complemented with comprehensive epidemiological studies
and continued monitoring of alloimmune-mediated adverse
events postlicencing. Finally, research over the coming years
is likely to further investigate alternative vaccine cell culture
systems, such as the insect cell-baculovirus expression sys-
tem used to produce novel influenza vaccines [57], and
manufacturing methods that reduce or remove potentially
allogeneic contaminants and thus mitigate the risk of allo-
geneic adverse reactions.
Key issues
● Bovine neonatal Pancytopenia (BNP) is a recently emerged
vaccine-induced disease of calves that highlights an impor-
tant vaccine safety issue.
● BNP is attributed to immunization of the calf’s mother with
a specific vaccine produced using an allogeneic cell line.
● Cell-line contaminants present in this vaccine induce alloan-
tibodies specific for Major-Histocompatibility class I antigens
● The alloantibodies are transferred from the mother to the
calf via the colostrum (first-milk), leading to profound
depletion of the calf’s peripheral blood and bone marrow
cells, which is often fatal.
● Many vaccines are produced in potentially allogeneic cell
lines, including several licensed human vaccines.
● While there are currently no reports of vaccine-induced
alloimmune adverse events in humans, the possibility of
such effects does not appear to have been thoroughly
investigated and are likely to affect specific populations
that are not normally studied in licensing trials, such as
transplant recipients and pregnant women.
● The occurrence of BNP highlights the need for careful
scrutiny of vaccines produced on allogeneic cell lines, the
importance of monitoring for the induction of alloantibo-
dies and the occurrence of adverse vaccine reactions in
both recipients and their offspring, and the difficulties
posed by monitoring for alloimmune-mediated adverse
reactions.
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